- Home
- NMRK vs BHVN Comparison
NMRK vs BHVN Comparison
Compare NMRK & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRK
- BHVN
- Stock Information
- Founded
- NMRK 1929
- BHVN 2013
- Country
- NMRK United States
- BHVN United States
- Employees
- NMRK N/A
- BHVN N/A
- Industry
- NMRK Real Estate
- BHVN Biotechnology: Pharmaceutical Preparations
- Sector
- NMRK Finance
- BHVN Health Care
- Exchange
- NMRK Nasdaq
- BHVN Nasdaq
- Market Cap
- NMRK 1.9B
- BHVN 1.9B
- IPO Year
- NMRK 2017
- BHVN 2017
- Fundamental
- Price
- NMRK $12.25
- BHVN $14.25
- Analyst Decision
- NMRK Strong Buy
- BHVN Strong Buy
- Analyst Count
- NMRK 4
- BHVN 14
- Target Price
- NMRK $15.67
- BHVN $58.85
- AVG Volume (30 Days)
- NMRK 1.2M
- BHVN 1.9M
- Earning Date
- NMRK 08-01-2025
- BHVN 08-07-2025
- Dividend Yield
- NMRK 0.98%
- BHVN N/A
- EPS Growth
- NMRK 81.01
- BHVN N/A
- EPS
- NMRK 0.38
- BHVN N/A
- Revenue
- NMRK $2,857,497,000.00
- BHVN N/A
- Revenue This Year
- NMRK $13.78
- BHVN N/A
- Revenue Next Year
- NMRK $9.47
- BHVN $59.97
- P/E Ratio
- NMRK $32.51
- BHVN N/A
- Revenue Growth
- NMRK 14.48
- BHVN N/A
- 52 Week Low
- NMRK $9.65
- BHVN $13.87
- 52 Week High
- NMRK $16.10
- BHVN $55.70
- Technical
- Relative Strength Index (RSI)
- NMRK 58.77
- BHVN 37.53
- Support Level
- NMRK $11.51
- BHVN $14.00
- Resistance Level
- NMRK $12.52
- BHVN $14.89
- Average True Range (ATR)
- NMRK 0.41
- BHVN 0.72
- MACD
- NMRK 0.08
- BHVN 0.07
- Stochastic Oscillator
- NMRK 74.33
- BHVN 16.38
About NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.